AstraZeneca AZN reported disappointing results from two late-stage studies that evaluated its investigational light chain depleter antibody, anselamimab, in certain patients with a rare disease called ...

NXC-201 shows promising efficacy and safety in treating relapsed/refractory AL Amyloidosis, with a 75% complete response rate. The NEXICART-2 study aims to evaluate ...

Pastor Kelvis Reid knew that he was taking a risk wrapping Christmas presents with his family, but he couldn't imagine spending the holidays any other way. He had just been diagnosed with a ...

Birtamimab did not meet the primary endpoint of time to all-cause mortality or the secondary endpoints Birtamimab development will be discontinued, including stopping the open label extension of the ...

Add Yahoo as a preferred source to see more of our stories on Google. The pathway uses the FDA-cleared echocardiography AI algorithm Us2.ai Viz.ai has entered a collaboration with Alnylam to advance ...